Abstract
Non-small-cell lung carcinoma (NSCLC) can be classified into several subtypes, where lung squamous carcinoma (LUSC) is one common subtype. Though miR-139-3p has been reported to be implicated in the development of various cancers, its mechanisms and functions remain unclear in LUSC. In this study, miR-139-3p was screened as one of the significantly down-regulated miRNAs in LUSC by an “edgeR” differential analysis based on TCGA database, which was verified by qRT-PCR in LUSC cell lines as well. The viability and cell cycle of the LUSC cells were examined by CCK-8 and flow cytometry, respectively, exhibiting that upregulating miR-139-3p restrained cell viability and thus accelerating the cell cycle. To explain this phenomenon, we further explored the downstream target gene through miRTarBase and starBase databases, where CHEK1 was predicted as one candidate. The targeting relationship was verified by a dual luciferase assay, identifying that CHEK1 could be targeted by miR-139-3p. Then, qRT-PCR and western blot analyses were performed to detect the expression of CHEK1 mRNA and proteins under the alteration of miR-139-3p expression. Rescue experiments were conducted to confirm the impacts of miR-139-3p/CHEK1 axis on the cell viability and cell cycle of LUSC. The results indicated that the effects of miR-139-3p on the LUSC cell phenotypes could be blocked by overexpressing CHEK1. In conclusion, our study provides a novel insight into the regulatory role of miR-139-3p in the development of LUSC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
The data used to support the findings of this study are available from the corresponding author upon request.
References
Bray, F., et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68, 394–424. https://doi.org/10.3322/caac.21492
Jacobsen, M. M., et al. (2017). Timeliness of access to lung cancer diagnosis and treatment: A scoping literature review. Lung Cancer, 112, 156–164. https://doi.org/10.1016/j.lungcan.2017.08.011
Ettinger, D. S., et al. (2010). Non-small cell lung cancer. Journal of the National Comprehensive Cancer Network, 8, 740–801. https://doi.org/10.6004/jnccn.2010.0056
Larsen, J. E., Cascone, T., Gerber, D. E., Heymach, J. V., & Minna, J. D. (2011). Targeted therapies for lung cancer: Clinical experience and novel agents. Cancer Journal, 17, 512–527. https://doi.org/10.1097/PPO.0b013e31823e701a
Tsai, J. H., Donaher, J. L., Murphy, D. A., Chau, S., & Yang, J. (2012). Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell, 22, 725–736. https://doi.org/10.1016/j.ccr.2012.09.022
Chen, W. J., et al. (2017). Implication of downregulation and prospective pathway signaling of microRNA-375 in lung squamous cell carcinoma. Pathology, Research and Practice, 213, 364–372. https://doi.org/10.1016/j.prp.2017.01.007
Li, H. Y., et al. (2017). miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer. Breast Cancer Research, 19, 133. https://doi.org/10.1186/s13058-017-0918-2
Yu, Y., et al. (2019). miR-190 enhances endocrine therapy sensitivity by regulating SOX9 expression in breast cancer. Journal of Experimental & Clinical Cancer Research, 38, 22. https://doi.org/10.1186/s13046-019-1039-9
Su, X. Y., et al. (2017). Follicle-stimulating hormone beta-subunit potentiates bone morphogenetic protein 9-induced osteogenic differentiation in mouse embryonic fibroblasts. Journal of Cellular Biochemistry, 118, 1792–1802. https://doi.org/10.1002/jcb.25849
Eslamizadeh, S., et al. (2018). The role of microRNA signature as diagnostic biomarkers in different clinical stages of colorectal cancer. Cell Journal, 20, 220–230. https://doi.org/10.22074/cellj.2018.5366
Zhang, W., Xu, J., Wang, K., Tang, X., & He, J. (2019). miR1393p suppresses the invasion and migration properties of breast cancer cells by targeting RAB1A. Oncology Reports, 42, 1699–1708. https://doi.org/10.3892/or.2019.7297
Zhao, P., et al. (2021). LncRNA PCAT6 regulates the progression of pituitary adenomas by regulating the miR-139-3p/BRD4 axis. Cancer Cell International, 21, 14. https://doi.org/10.1186/s12935-020-01698-7
Ma, Y., Chen, Z., & Yu, G. (2020). microRNA-139-3p inhibits malignant behaviors of laryngeal cancer cells via the KDM5B/SOX2 axis and the Wnt/beta-catenin pathway. Cancer Manag Res, 12, 9197–9209. https://doi.org/10.2147/CMAR.S268871
Ni, Z. Z., et al. (2020). Identification of ELAVL1 gene and miRNA-139-3p involved in the aggressiveness of NSCLC. European Review for Medical and Pharmacological Sciences, 24, 9453–9464. https://doi.org/10.26355/eurrev_202009_23030
Liu, X., et al. (2021). Integrated analysis of the m6A-related lncRNA identified lncRNA ABALON/miR-139-3p/NOB1 axis was involved in the occurrence of lung cancer. Cancer Manag Res, 13, 8707–8722. https://doi.org/10.2147/CMAR.S339032
Sanchez, Y., et al. (1997). Conservation of the Chk1 checkpoint pathway in mammals: Linkage of DNA damage to Cdk regulation through Cdc25. Science, 277, 1497–1501. https://doi.org/10.1126/science.277.5331.1497
Walworth, N., Davey, S., & Beach, D. (1993). Fission yeast chk1 protein kinase links the rad checkpoint pathway to cdc2. Nature, 363, 368–371. https://doi.org/10.1038/363368a0
Zhang, Y., & Hunter, T. (2014). Roles of Chk1 in cell biology and cancer therapy. International Journal of Cancer, 134, 1013–1023. https://doi.org/10.1002/ijc.28226
Xu, J., et al. (2013). Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer. Oncogene, 32, 976–987. https://doi.org/10.1038/onc.2012.121
Bai, X., et al. (2018). Serine/Threonine Kinase CHEK1-dependent transcriptional regulation of RAD54L promotes proliferation and radio resistance in glioblastoma. Translational Oncology, 11, 140–146. https://doi.org/10.1016/j.tranon.2017.11.007
Xue, F., Li, Q. R., Xu, Y. H., & Zhou, H. B. (2019). MicroRNA-139-3p inhibits the growth and metastasis of ovarian cancer by inhibiting ELAVL1. Oncotargets and Therapy, 12, 8935–8945. https://doi.org/10.2147/OTT.S210739
Shi, L., Yuan, Y., & Li, H. Y. (2019). MicroRNA-139-3p suppresses growth and metastasis of glioblastoma via inhibition of NIN1/RPNI2 binding protein 1 homolog. European Review for Medical and Pharmacological Sciences, 23, 4264–4274. https://doi.org/10.26355/eurrev_201905_17931
Wu, Y., et al. (2020). LINC00511 promotes lung squamous cell carcinoma proliferation and migration via inhibiting miR-150-5p and activating TADA1. Transl Lung Cancer Res, 9, 1138–1148. https://doi.org/10.21037/tlcr-19-701
Guo, L., et al. (2020). Fibroblastderived exosomal microRNA369 potentiates migration and invasion of lung squamous cell carcinoma cells via NF1mediated MAPK signaling pathway. International Journal of Molecular Medicine, 46, 595–608. https://doi.org/10.3892/ijmm.2020.4614
Bao, J., et al. (2018). MiR-126 negatively regulates PLK-4 to impact the development of hepatocellular carcinoma via ATR/CHEK1 pathway. Cell Death & Disease, 9, 1045. https://doi.org/10.1038/s41419-018-1020-0
Zhang, W. H., Poh, A., Fanous, A. A., & Eastman, A. (2008). DNA damage-induced S phase arrest in human breast cancer depends on Chk1, but G2 arrest can occur independently of Chk1, Chk2 or MAPKAPK2. Cell Cycle, 7, 1668–1677. https://doi.org/10.4161/cc.7.11.5982
Wang, F. Z., et al. (2014). The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells. Apoptosis, 19, 1389–1398. https://doi.org/10.1007/s10495-014-1010-3
Kim, M. K., James, J., & Annunziata, C. M. (2015). Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells. BMC Cancer, 15, 196. https://doi.org/10.1186/s12885-015-1231-z
Jiang, J., et al. (2020). HOTAIR promotes paclitaxel resistance by regulating CHEK1 in ovarian cancer. Cancer Chemotherapy and Pharmacology, 86, 295–305. https://doi.org/10.1007/s00280-020-04120-1
Sankunny, M., et al. (2014). Targeted inhibition of ATR or CHEK1 reverses radioresistance in oral squamous cell carcinoma cells with distal chromosome arm 11q loss. Genes, Chromosomes & Cancer, 53, 129–143. https://doi.org/10.1002/gcc.22125
Funding
None.
Author information
Authors and Affiliations
Contributions
XZ: conceptualization, methodology, writing—original draft. YZ: validation, formal analysis, investigation, SW: data curation, visualization. BJ: resources, supervision. YL: writing—review and editing, project administration.
Corresponding author
Ethics declarations
Conflict of interest
All authors declare that they have no potential conflicts of interest.
Ethical Approval
Not applicable.
Consent to Participate
Not applicable.
Consent for Publication
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Zheng, X., Zhang, Y., Wu, S. et al. MiR-139-3p Targets CHEK1 Modulating DNA Repair and Cell Viability in Lung Squamous Carcinoma Cells. Mol Biotechnol 64, 832–840 (2022). https://doi.org/10.1007/s12033-022-00462-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12033-022-00462-8